QuicDNA Max Research Programme – multi site, multi-centre, non-interventional, biomarker platform study. Assessing blood based ctDNA (circulating tumour) testing to guide cancer care across multiple cancer types

QuicDNA Max Research Programme (Multi- Site)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12373430

Enrollment

1000

Registered

2026-05-01

Start date

2026-03-31

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individuals with radiologically suspected or confirmed advanced cancers, or those who have developed resistance to existing therapies and have radiological evidence of disease progression Cancer

Interventions

The QuicDNA Max programme is a platform-based, prospective, multi-centre, exploratory diagnostic study conducted across NHS hospitals and clinics. The study is designed as an open-label, non-intervent

Eligibility

Sex/Gender

All

Age

16 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Are willing and able to provide written informed consent 2. Are aged 16 years or older 3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 4. Have a suspected or confirmed diagnosis of cancer 5. Meet any additional tumour-specific eligibility criteria, as outlined in the relevant sub-protocols

Exclusion criteria

Exclusion criteria: 1. Are unable or unwilling to comply with study procedures 2. Meet any tumour-specific exclusion criteria as defined in the relevant sub-protocols

Design outcomes

Primary

Measure	Time frame
This is a non-interventional, exploratory study. Analyses will be mainly descriptive, focusing on metrics such as ctDNA turnaround time specified in the outcomes section including, concordance with tissue, and rates of actionable mutations. Outcomes will be analysed separately for each tumour-specific sub-protocol. Where appropriate, simple statistical tests (e.g. chi-square, t-tests) may be used. No safety analyses are required. Exploratory sub-group analyses (e.g. by cancer type or treatment status) will be detailed in sub-protocols. Interim analyses may be performed to assess feasibility, assay performance, or recruitment progress, but will not influence trial continuation decisions unless specified. Primary outcomes tailored to specific tumour types and clinical settings will be defined in the corresponding sub-protocols	—

Measure

Time frame

This is a non-interventional, exploratory study. Analyses will be mainly descriptive, focusing on metrics such as ctDNA turnaround time specified in the outcomes section including, concordance with tissue, and rates of actionable mutations. Outcomes will be analysed separately for each tumour-specific sub-protocol. Where appropriate, simple statistical tests (e.g. chi-square, t-tests) may be used. No safety analyses are required. Exploratory sub-group analyses (e.g. by cancer type or treatment status) will be detailed in sub-protocols. Interim analyses may be performed to assess feasibility, assay performance, or recruitment progress, but will not influence trial continuation decisions unless specified. Primary outcomes tailored to specific tumour types and clinical settings will be defined in the corresponding sub-protocols

—

Secondary

Measure	Time frame
Secondary outcomes will be specified in each tumour-specific sub-protocol, according to clinical context and research objectives	—

Countries

United Kingdom, Wales

Contacts

Public ContactGeorgina Gardner

QuicDNAMax@cardiff.ac.uk+44 2920687950

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 16, 2026